Yingkai Li

585 total citations
27 papers, 210 citations indexed

About

Yingkai Li is a scholar working on Neurology, Cardiology and Cardiovascular Medicine and Infectious Diseases. According to data from OpenAlex, Yingkai Li has authored 27 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Neurology, 9 papers in Cardiology and Cardiovascular Medicine and 7 papers in Infectious Diseases. Recurrent topics in Yingkai Li's work include Myasthenia Gravis and Thymoma (15 papers), Antifungal resistance and susceptibility (7 papers) and Peripheral Neuropathies and Disorders (5 papers). Yingkai Li is often cited by papers focused on Myasthenia Gravis and Thymoma (15 papers), Antifungal resistance and susceptibility (7 papers) and Peripheral Neuropathies and Disorders (5 papers). Yingkai Li collaborates with scholars based in China and United States. Yingkai Li's co-authors include Weibin Liu, Jeffrey T. Guptill, Xin Huang, John S. Yi, Pei Chen, Manisha Chopra, James F. Howard, Vern C. Juel, Lisa D. Hobson‐Webb and Janice M. Massey and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Scientific Reports.

In The Last Decade

Yingkai Li

23 papers receiving 206 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yingkai Li China 9 124 50 32 31 23 27 210
Anna Green United Kingdom 7 92 0.7× 61 1.2× 9 0.3× 30 1.0× 12 0.5× 15 197
Francisco Morandeira Spain 10 65 0.5× 39 0.8× 13 0.4× 29 0.9× 53 2.3× 29 241
Laura Wiffen United Kingdom 6 31 0.3× 78 1.6× 15 0.5× 24 0.8× 40 1.7× 13 170
Batoul Hammoud United States 7 82 0.7× 48 1.0× 6 0.2× 19 0.6× 4 0.2× 12 171
Marie Koubi France 6 88 0.7× 156 3.1× 9 0.3× 20 0.6× 29 1.3× 9 220
Paolo Stobbione Italy 5 90 0.7× 129 2.6× 6 0.2× 23 0.7× 23 1.0× 7 208
Adrien Picod France 8 17 0.1× 24 0.5× 23 0.7× 23 0.7× 50 2.2× 26 170
Jean‐Baptiste Julla France 8 22 0.2× 33 0.7× 7 0.2× 40 1.3× 34 1.5× 22 176
Fabio Ferrari Italy 6 26 0.2× 33 0.7× 26 0.8× 21 0.7× 6 0.3× 14 111
Artemis Papadaki United Kingdom 4 65 0.5× 69 1.4× 5 0.2× 15 0.5× 41 1.8× 8 175

Countries citing papers authored by Yingkai Li

Since Specialization
Citations

This map shows the geographic impact of Yingkai Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingkai Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingkai Li more than expected).

Fields of papers citing papers by Yingkai Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingkai Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingkai Li. The network helps show where Yingkai Li may publish in the future.

Co-authorship network of co-authors of Yingkai Li

This figure shows the co-authorship network connecting the top 25 collaborators of Yingkai Li. A scholar is included among the top collaborators of Yingkai Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yingkai Li. Yingkai Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lee, Sean M., Vern C. Juel, Yingkai Li, et al.. (2025). Serum fibrinogen is not elevated in patients with myasthenia gravis. Scientific Reports. 15(1). 13013–13013. 1 indexed citations
3.
Li, Yingkai, Pei Chen, Xin Huang, et al.. (2024). Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients. Journal of Neuroimmunology. 396. 578464–578464. 1 indexed citations
4.
Zhang, Jichao, Cong-Cong Zhang, Shijuan Gao, et al.. (2024). PALMD haploinsufficiency aggravates extracellular matrix remodeling in vascular smooth muscle cells and promotes calcification. American Journal of Physiology-Cell Physiology. 327(4). C1012–C1022. 2 indexed citations
5.
Zhou, Qin, Xiaoxiao Zhao, Mengzhu Wang, et al.. (2024). Combined Use of Magnetization Transfer Ratio and T2-Mapping to Evaluate Extraocular Muscle Pathophysiology in Myasthenia Gravis with Ophthalmoparesis. International Journal of Medical Sciences. 21(14). 2799–2806.
6.
7.
Li, Yingkai, Vern C. Juel, Lisa D. Hobson‐Webb, et al.. (2023). Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis: follow up survey. Macedonian Journal of Medical Sciences (University of Skopje). 4(1).
8.
Li, Yingkai, Zheng Wu, Wenzheng Li, et al.. (2022). The predictive value of the triglyceride—glucose index for cardiovascular events in patients with coronary chronic total occlusion. Cardiovascular Diabetology. 21(1). 149–149. 14 indexed citations
9.
10.
Huang, Xin, Hao Ran, Yingkai Li, et al.. (2022). Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients. Frontiers in Neurology. 13. 961628–961628. 2 indexed citations
11.
Li, Yingkai, et al.. (2022). The clinical need for clustered AChR cell-based assay testing of seronegative MG. Journal of Neuroimmunology. 367. 577850–577850. 18 indexed citations
12.
Li, Yingkai, Ruyan Zhang, Yongqing Liu, et al.. (2022). Risk factors for cardiac rupture after acute ST-segment elevation myocardial infarction during the percutaneous coronary intervention era: a retrospective case-control study. Journal of Thoracic Disease. 14(4). 1256–1266. 6 indexed citations
13.
Li, Yingkai, et al.. (2021). Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clinical Immunology. 231. 108830–108830. 7 indexed citations
14.
Li, Yingkai, et al.. (2021). Normative dataset for plasma cytokines in healthy human adults. SHILAP Revista de lepidopterología. 35. 106857–106857. 16 indexed citations
15.
Li, Yingkai, Jeffrey T. Guptill, James F. Howard, et al.. (2020). Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. Journal of Neuroimmunology. 345. 577279–577279. 20 indexed citations
16.
Ma, Qian, Hao Ran, Yingkai Li, et al.. (2020). Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. Clinical Immunology. 218. 108492–108492. 15 indexed citations
17.
Li, Yingkai, et al.. (2019). A case presentation of patient from northern China with endomyocardial fibrosis. BMC Cardiovascular Disorders. 19(1). 313–313. 1 indexed citations
18.
Huang, Xin, et al.. (2018). Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China. Frontiers in Neurology. 9. 77–77. 41 indexed citations
19.
Li, Yingkai, Jeffrey T. Guptill, Janice M. Massey, et al.. (2018). Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Experimental Neurology. 312. 43–50. 27 indexed citations
20.
Chen, Pei, Yingkai Li, Hao Huang, et al.. (2018). Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis. Clinical Immunology. 205. 130–137. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Green Breakdown of academic impact, for papers by Francisco Morandeira Breakdown of academic impact, for papers by Laura Wiffen Breakdown of academic impact, for papers by Batoul Hammoud Breakdown of academic impact, for papers by Marie Koubi Breakdown of academic impact, for papers by Paolo Stobbione Breakdown of academic impact, for papers by Adrien Picod Breakdown of academic impact, for papers by Jean‐Baptiste Julla Breakdown of academic impact, for papers by Fabio Ferrari Breakdown of academic impact, for papers by Artemis Papadaki
Rankless by CCL
2026